REVOLUTION MEDICINES

Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress

11 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021

04 Aug 2021 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1

24 Jun 2021 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors

10 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

02 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit

18 May 2021 07:30:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress

10 May 2021 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting

03 May 2021 07:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors

21 Apr 2021 07:00:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021

11 Mar 2021 16:05:01 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

09 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress

02 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences

18 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

08 Feb 2021 16:01:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock

03 Feb 2021 23:30:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Proposed Public Offering of Common Stock

01 Feb 2021 16:01:00 By Nasdaq GlobeNewswire

Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference

05 Jan 2021 07:30:00 By Nasdaq GlobeNewswire